

# PERK Polyclonal Antibody

Catalog # AP71849

### **Product Information**

Application WB, IHC-P, IF Primary Accession O9NZI5

Reactivity Human, Mouse, Rat

HostRabbitClonalityPolyclonalCalculated MW125216

## **Additional Information**

**Gene ID** 9451

Other Names EIF2AK3; PEK; PERK; Eukaryotic translation initiation factor 2-alpha kinase 3;

PRKR-like endoplasmic reticulum kinase; Pancreatic eIF2-alpha kinase; HsPEK

**Dilution** WB~~1:1000 IHC-P~~N/A IF~~IF: 1:50-200 Western Blot: 1/500 - 1/2000.

Immunohistochemistry: 1/100 - 1/300. ELISA: 1/40000. Not yet tested in other

applications.

Format Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% (W/V) sodium

azide.

Storage Conditions -20°C

#### **Protein Information**

Name EIF2AK3 {ECO:0000303 | PubMed:10932183,

ECO:0000312 | HGNC:HGNC:3255}

**Function** Metabolic-stress sensing protein kinase that phosphorylates the alpha

subunit of eukaryotic translation initiation factor 2 (EIF2S1/eIF-2-alpha) in response to various stress, such as unfolded protein response (UPR)

(PubMed: 10026192, PubMed: 10677345, PubMed: 11907036,

PubMed: 12086964, PubMed: 25925385, PubMed: 31023583). Key effector of the integrated stress response (ISR) to unfolded proteins: EIF2AK3/PERK specifically recognizes and binds misfolded proteins, leading to its activation

and EIF2S1/eIF-2-alpha phosphorylation (PubMed: 10677345,

PubMed:<u>27917829</u>, PubMed:<u>31023583</u>). EIF2S1/eIF-2-alpha phosphorylation in response to stress converts EIF2S1/eIF-2-alpha in a global protein synthesis inhibitor, leading to a global attenuation of cap-dependent translation, while concomitantly initiating the preferential translation of ISR-specific mRNAs, such as the transcriptional activators ATF4 and QRICH1, and hence allowing

ATF4- and QRICH1-mediated reprogramming (PubMed: 10026192, PubMed: 10677345, PubMed: 31023583, PubMed: 33384352). The

EIF2AK3/PERK- mediated unfolded protein response increases mitochondrial oxidative phosphorylation by promoting ATF4-mediated expression of COX7A2L/SCAF1, thereby increasing formation of respiratory chain supercomplexes (PubMed:31023583). In contrast to most subcellular compartments, mitochondria are protected from the EIF2AK3/PERK-mediated unfolded protein response due to EIF2AK3/PERK inhibition by ATAD3A at mitochondria-endoplasmic reticulum contact sites (PubMed:39116259). In addition to EIF2S1/eIF-2-alpha, also phosphorylates NFE2L2/NRF2 in response to stress, promoting release of NFE2L2/NRF2 from the BCR(KEAP1) complex, leading to nuclear accumulation and activation of NFE2L2/NRF2 (By similarity). Serves as a critical effector of unfolded protein response (UPR)-induced G1 growth arrest due to the loss of cyclin-D1 (CCND1) (By similarity). Involved in control of mitochondrial morphology and function (By similarity).

**Cellular Location** 

Endoplasmic reticulum membrane {ECO:0000250 | UniProtKB:Q9Z2B5}; Single-pass type I membrane protein. Note=Localizes to the Localizes to endoplasmic reticulum membrane (By similarity). Also present at mitochondria-endoplasmic reticulum contact sites; where it interacts with ATAD3A (PubMed:39116259). {ECO:0000250 | UniProtKB:Q9Z2B5, ECO:0000269 | PubMed:39116259}


**Tissue Location** 

Ubiquitous. A high level expression is seen in secretory tissues.


## **Background**

Metabolic-stress sensing protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (eIF-2-alpha/EIF2S1) on 'Ser-52' during the unfolded protein response (UPR) and in response to low amino acid availability. Converts phosphorylated eIF-2-alpha/EIF2S1 either in a global protein synthesis inhibitor, leading to a reduced overall utilization of amino acids, or to a translation initiation activator of specific mRNAs, such as the transcriptional activator ATF4, and hence allowing ATF4-mediated reprogramming of amino acid biosynthetic gene expression to alleviate nutrient depletion. Serves as a critical effector of unfolded protein response (UPR)- induced G1 growth arrest due to the loss of cyclin-D1 (CCND1). Involved in control of mitochondrial morphology and function.


## **Images**




Immunofluorescence analysis of rat-lung tissue. 1,PERK Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B





Immunofluorescence analysis of rat-lung tissue. 1,PERK Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B




Immunofluorescence analysis of rat-spleen tissue. 1,PERK Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B

















Immunofluorescence analysis of rat-spleen tissue. 1,PERK Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B

Immunofluorescence analysis of mouse-lung tissue.

1,PERK Polyclonal Antibody(red) was diluted at

1:200(4°C,overnight). 2, Cy3 labled Secondary antibody
was diluted at 1:300(room temperature, 50min).3, Picture
B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI.
Picture C: merge of A+B

Immunofluorescence analysis of mouse-lung tissue.

1,PERK Polyclonal Antibody(red) was diluted at

1:200(4°C,overnight). 2, Cy3 labled Secondary antibody
was diluted at 1:300(room temperature, 50min).3, Picture
B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI.
Picture C: merge of A+B


Immunohistochemical analysis of paraffin-embedded Human-Tonsil tissue. 1,PERK Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by secondary antibody only.

Immunohistochemical analysis of paraffin-embedded Human-lung tissue. 1,PERK Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by secondary antibody only.


Immunohistochemical analysis of paraffin-embedded Human-stomach tissue. 1,PERK Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by secondary antibody only.

Immunohistochemical analysis of paraffin-embedded Human-stomach-cancer tissue. 1,PERK Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by secondary antibody only.


Immunohistochemical analysis of paraffin-embedded Human-Appendix tissue. 1,PERK Polyclonal Antibody was




diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by secondary antibody only.




Immunohistochemical analysis of paraffin-embedded Rat-heart tissue. 1,PERK Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by secondary antibody only.




Immunohistochemical analysis of paraffin-embedded Rat-liver tissue. 1,PERK Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by secondary antibody only.



Immunohistochemical analysis of paraffin-embedded Rat-lung tissue. 1,PERK Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by secondary antibody only.




Immunohistochemical analysis of paraffin-embedded Rat-kidney tissue. 1,PERK Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by secondary antibody only.




Immunohistochemical analysis of paraffin-embedded Mouse-heart tissue. 1,PERK Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by secondary antibody only.

Immunohistochemical analysis of paraffin-embedded Mouse-liver tissue. 1,PERK Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by



secondary antibody only.



Immunohistochemical analysis of paraffin-embedded Mouse-lung tissue. 1,PERK Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by secondary antibody only.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.